Table 1.

Baseline characteristics and sum-scores of 87 participants included in this study: 16 healthy controls, 20 recently diagnosed myasthenia gravis (MG) patients, 19 chronic MG patients, 14 seronegative MG (SNMG) patients, 6 chronic progressive external ophthalmoplegia (CPEO) patients, 6 oculopharyngeal muscular dystrophy (OPMD) patients and 6 Graves’ orbitopathy (GO) patients. Data are presented as number of patients (%) for categorical variables and as mean±SD for continuous variables. Synoptophore abnormalities is defined as having limited duction angles in any direction in one or both eyes. Hess-chart abnormalities is defined as having gaze deviations between the eyes above 5 degrees in any direction

	MG Recently diagnosed n = 20	MG Chronic n = 19	MG Seronegative n = 14	CPEO n = 6	OPMD n = 6	GO n = 6	Healthy controls n = 16	p-value
Age (yrs)	59±19	51±16	57±9	49±14	62±10	44±12	54±13	0.243
Sex								0.754
Female	7 (35%)	9 (47%)	7 (50%)	3 (50%)	4 (67%)	4 (67%)	9 (56%)
Male	13 (65%)	10 (53%)	7 (50%)	3 (50%)	2 (33%)	2 (33%)	7 (44%)
Phenotype								0.105
Ocular	12 (60%)	6 (32%)	9 (64%)	-	-	-	-
Generalized	8 (40%)	13 (68%)	5 (36%)	-	-	-	-
Disease duration (months)	4.0±2.2	75.6±87.9	25.6±60.5	-	-	22.8±35.9*	-	< 0.0001
MG-ADL	5.8±3.3	5.5±4.2	5.0±2.7	-	-	-	-	0.791
MG-ADL (ocular items)	2.8±1.1	1.7±0.8	2.9±1.2					0.165
QMG	9.2±6.0	9.8±7.7	8.3±4.6	-	-	-	-	0.812
QMG (ocular items)	2.2±0.7	1.2±0.7	2.5±1.0					0.365
Pyridostigmine on study day	25%	15%	14%	-	-	-	-	0.680
Hess-chart abnormalities	15	15	11	6	5	5	0
Synoptophore abnormalities	9	10	7	6	5	1	0
Ptosis at visit	10	5	5	5	5	0	0

^*Two Graves’ orbitopathy patients were diagnosed longer than>one year ago and four patients<one year ago.